Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

Tuberculosis Clinical Trial

Official title:

Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02602509
• Other study ID #: Celecoxib_WBA
• Status: Completed
• Phase: Phase 1
• First received: November 6, 2015
• Last updated: April 12, 2017
• Start date: November 2015
• Est. completion date: February 2016

Study information

• Verified date: November 2015
• Source: National University Hospital, Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the bactericidal activity against Mycobacterium tuberculosis of celecoxib in combination with established drugs used to treat tuberculosis (TB). Pharmacokinetics (PK) and whole blood bactericidal activity (WBA) will be measured in healthy volunteers following administration of the study drugs alone and in combination.

Description:

The whole blood bactericidal activity (WBA) assay is an ex vivo model for measuring the combined effects of administered drugs, host factors and strain factors on mycobacterial sterilisation. If performed in parallel with PK measurements, the method can be used to evaluate the effect of drugs throughout the dosing cycle. Celecoxib is a COX-2 inhibitor with immuno-modulatory properties important in the host defence against tuberculosis (TB). The aim of this trial is to investigate the effect on WBA of manipulation of the host response to TB using celecoxib, in combination with established TB drugs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Aged over 21 years and below 60 years old

2. Male or female willing to comply with the study visits and procedures

3. Willing and able to provide written informed consent

Exclusion Criteria:

1. Women who are currently pregnant or breastfeeding

2. Body weight below 50kg

3. Clinical signs of active TB in the opinion of the investigator

4. Previous hypersensitivity, intolerance or allergy to rifampicin, pyrazinamide, COX-2 inhibitors, non-steroidal anti-inflammatory drugs or sulfonamides

5. Current use of any drugs or medication known to have an interaction with rifampicin, pyrazinamide or celecoxib

6. Current use or use in the last 2 weeks of non-steroidal anti-inflammatory drugs or COX-2 inhibitors

7. Current use or use in the last 2 weeks of any drugs, over the counter or herbal preparations that are known or potential inhibitors or inducers of cytochrome P450 enzymes

8. Evidence of renal or hepatic dysfunction or any clinically significant deviation from normal during screening including laboratory determinations

9. Known hepatic disease, recent hepatitis (within last 6 months) or alcohol abuse

10. Known cardiovascular disease, heart failure, stroke or current cardiovascular risk factors

11. Known peptic ulcer disease, previous gastrointestinal bleed or current risk factors for gastrointestinal events

12. Acute or previous gout, acute porphyria

13. Any other significant condition that would, in the opinion of the investigator, compromise the volunteer's safety or outcome in the trial

14. Current participation in other clinical intervention trial or research protocol

Related Conditions & MeSH terms

• Mycobacterium Infections
• Tuberculosis

Intervention

Drug:
• Celecoxib

• Rifampicin

• Pyrazinamide

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Log change CFU.day (cumulative over 8 hours) calculated from Mycobacteria Growth Indicator Tube (MGIT) Time to Positivity	Cumulative whole blood bactericidal activity (WBA)	8 hours
Secondary	Plasma concentrations of study drugs to determine the Area Under the Curve (AUC)		8 hours
Secondary	Plasma concentrations of study drugs to determine the Maximum Plasma Concentration (Cmax)		8 hours